ClinicalTrials.gg
Not yet recruitingNCT06279286Updated Apr 23, 2024

Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder

A Phase 1/2 interventional study of HS-10506 and Placebo in Insomnia Disorder, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.

Planned enrollment
17th of 162
312 · median 88
Started
2024
with 44 others
Phase 1/2
2 of 198
1 open now
Primary completion
2025-01
later than 11 of 87 live
Registered
95th of 198
by date

Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 17th largest by planned enrollment of the 162 interventional ones that give a count, is one of 45 that started in 2024, is one of 2 in phase 1/2, reaches primary completion later than 11 of the 87 other live ones, and was the 95th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 730 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 389 Sleep Initiation and Maintenance Disorders studies recruiting now, 152 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 108 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, or all of them as a file.
02

Study summary

The primary purpose of this phase Ⅰb/Ⅱ study is to investigate the safety, tolerability, pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) after multiple dose administration and the efficacy of HS-10506 (change versus placebo) on latency to persistent sleep (LPS) measured by polysomnography (PSG) in Chinese adult participants with insomnia disorder.

Read the detailed description

This study consists of two stages: phase Ib and phase II. Primary objective of phase Ib Study is to assess the safety, tolerability of HS-10506 in subjects with insomnia disorder. .

Primary objective of phase II Study is to assess the efficacy of HS-10506 in subjects with insomnia disorder.

03

Conditions studied

  • Insomnia Disorder

Keywords

  • Clinical trial
  • insomnia disorder
  • phase Ⅰb/Ⅱ
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be 18 to 64 years of age, inclusive
  2. Subjects are required to voluntarily sign the form;
  3. (BMI): for phase Ib, males must weigh at least 50 kilogram (kg), females at least 45 kg, and BMI (weight/height2 [kg/m2]) must be in the range of 18 to 30 kg/m2 (inclusive) for both gender; for phase II, BMI must be in the range of 18 to 35 kg/m2 (inclusive);
  4. Participant must meet (5th edition) (DSM-5) criteria for insomnia disorder;
  5. Participants must have Insomnia Severity Index (ISI) scores >=15 at screening and baseline;
  6. Subjective sleep assessment: for phase Ib, subjects must have a self-reported sleep latency (sSOL) >= 30 minutes, a subjective sleep awakening time (sWASO) >= 30 minutes, and a subjective total sleep time (sTST) =\< 6.5 hours using the sleep diary for at least three nights every week in the last 1 month prior to screening; For phase II, subjects must have an sSOL >= 30 minutes, sWASO >= 30 minutes, and sTST =\< 6.5 hours for at least three nights every week within one month prior to screening; and sSOL >= 30 minutes, sWASO >= 30 minutes, and sTST =\< 6.5 hours for at least 3 nights from sleep diary in the last 7 days;
  7. PSG: for phase Ib, participants must demonstrate an LPS >= 20 minutes, TST \< 420 minutes, and WASO >= 30 minutes at screening; for phase II, participants must demonstrate a 2-night mean LPS >= 30 minutes with neither night \< 20 minutes, a 2-night mean TST =\< 6.5 hours with neither night > 7 hours and a 2-night mean WASO >= 30 minutes with neither nigh \< 20 minutes.

Exclusion criteria

Exclusion Criteria:

  1. Has history of or current sleep-wake disorders or sleep-related breathing disorders other than insomnia disorder, such as restless legs syndrome, periodic limb movement disorder, circadian rhythm disorder, narcolepsy, rapid eye movement sleep phase (REM) behavioral disorders, and obstructive sleep apnea;
  2. Has a hypopnea index (AHI) >10 times/hour or periodic leg movement index (PLMI) >10 times/hour monitored by PSG at screening or run-in period;
  3. Has history of or current neurodevelopmental retardation, cognitive impairment, epilepsy, schizophrenia, bipolar disorder, hyperthyroidism, cancer, severe cardio-cerebrovascular diseases or respiratory diseases; or and/or unstable neurological, psychiatric, respiratory, cardiovascular, digestive, immunologic, urologic, endocrine diseases within the past 3 months prior to screening; or other systemic diseases that are inappropriate for the study;
  4. (For phase II only) Has a Hamilton Anxiety Scale (HAMA) score >= 14 or Hamilton Depression Scale (HAMD-17) score >= 18;
  5. Use of any medication that may affect the pharmacokinetics of HS-10506 within the past 2 weeks or 5 half-lives of the medication;
  6. Use of any medication that may affect sleep-wake function, or any other prohibited central nervous system active medications within 1 week or 5 half-lives of the medication;
  7. Has received systemic hypnotherapy, cognitive behavioral therapy (CBT), or other non-pharmacological treatments for insomnia in last 4 weeks or have plans during the study;
  8. Working across 3 or more time zones or shift work within 2 weeks prior to screening;
  9. Regularly naps more than 3 naps per week for > 1 hour each time within the past 2 weeks prior to screening;
  10. Has a risk of suicide according to the Columbia Suicide Severity Rating Scale (C-SSRS), or has a high risk of suicide at the discretion of the investigator;
  11. Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
312 participants (estimated)

Study arms

  • Experimental
    HS-10506, 10 milligram (mg) and placebo

    Phase Ib part: Participants will receive either 10mg of HS-10506 or matching placebo at night on Day 1 up to Day 5. Phase II part: Participants will receive either 10mg of HS-10506 or matching placebo at night on Day 1 up to Day 28.

    Drug: HS-10506 · Drug: Placebo

  • Experimental
    HS-10506, 20 milligram (mg) and placebo

    Phase Ib part: Participants will receive either 20mg of HS-10506 or matching placebo at night on Day 1 up to Day 5. Phase II part: Participants will receive either 20mg of HS-10506 or matching placebo at night on Day 1 up to Day 28.

    Drug: HS-10506 · Drug: Placebo

  • Experimental
    HS-10506, 40 milligram (mg) and placebo

    Phase Ib part: Participants will receive either 40mg of HS-10506 or matching placebo at night on Day 1 up to Day 5. Phase II part: Participants will receive either 40mg of HS-10506 or matching placebo at night on Day 1 up to Day 28.

    Drug: HS-10506 · Drug: Placebo

  • Experimental
    HS-10506, 80 milligram (mg) and placebo

    Phase Ib part: Participants will receive either 80mg of HS-10506 or matching placebo at night on Day 1 up to Day 5. Phase II part: Participants will receive either 80mg of HS-10506 or matching placebo at night on Day 1 up to Day 28.

    Drug: HS-10506 · Drug: Placebo

Interventions

  • HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.

  • DrugPlacebo

    Placebo, placebo tablets matching the HS-10506 tablets

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AE)

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Baseline up to the end of the study (3 days after the last dose) or early withdrawal

  2. Incidence and severity of serious adverse events (SAE)

    An SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: Baseline up to the end of the study (3 days after the last dose) or early withdrawal

  3. Changes in laboratory test before and after drug administration

    Number of participants with clinically significant laboratory abnormalities, including complete blood cell count, urinalysis, serum chemistry, coagulation function were reported.

    Time frame: Baseline up to the end of the study (3 days after last dose) or early withdrawal

  4. Changes in ECG before and after drug administration

    Number of participants with clinically significant ECG abnormalities were reported.

    Time frame: Baseline up to the end of the study (3 days after last dose) or early withdrawal

  5. Changes in Karolinska Sleepiness Scale (KSS) scores before and after drug administration

    The KSS is a patient-reported assessment of drowsiness level at the time of scale administration.

    Time frame: From start of the drug administration to the next day of the last dose or early withdrawal

  6. Change from baseline in the mean LPS measured by PSG on Night 13 and Night 14

    LPS is the time in minutes from 'lights out' that marks the starting of total recording time to the first epoch recorded as sleep.

    Time frame: Baseline, Night 13& Night 14

Secondary outcomes

  1. The maximum plasma concentration (C[max])

    The C\[max\] is the maximum observed plasma concentration and will be determined for HS-10506.

    Time frame: Baseline up to 48 hours after the last dose or early withdrawal

  2. Time to reach the maximum plasma concentration (T[max])

    Time to reach maximum observed plasma concentration (T\[max\]) of HS-10506.

    Time frame: Baseline up to 48 hours after the last dose or early withdrawal

  3. Area under the plasma concentration-time curve from time zero to last time of quantifiable concentration (AUC[0-t])

    Area under the concentration-time curve from time zero to last time of quantifiable concentration of HS-10506.

    Time frame: Baseline up to 48 hours after the last dose or early withdrawal

  4. Terminal elimination half-life (t1/2)

    Apparent terminal elimination half-life of HS-10506.

    Time frame: Baseline up to 48 hours after the last dose or early withdrawal

  5. Change in latency to persistent sleep (LPS) relative to baseline on night 5 of PSG monitoring

    Latency to persistent sleep (LPS) is the time in minutes from 'lights out' that marks the starting of total recording time to the first epoch recorded as sleep over PSG assessment.

    Time frame: Baseline and Night 5

  6. Change in Wake After Sleep Onset (WASO) relative to baseline on night 5 of PSG monitoring

    Wake After Sleep Onset (WASO) is defined as the duration of wakefulness from the onset of persistent sleep over the PSG assessment.

    Time frame: Baseline and Night 5

  7. Change from baseline in mean LPS measured by PSG

    Latency to Persistent Sleep (LPS) is the time in minutes from 'lights out' that marks the starting of total recording time to the first epoch recorded as sleep over PSG assessment.

    Time frame: Baseline up to 28 days.

  8. Change from baseline in mean TST measured by PSG

    Total sleep time (TST) is the total amount of sleep time scored during the total recording time over PSG assessment.

    Time frame: Baseline up to 28 days.

  9. Change from baseline in mean WASO measured by PSG

    Wake after initial sleep onset (WASO) is defined as the duration of wakefulness from the onset of persistent sleep over PSG assessment.

    Time frame: Baseline up to 28 days.

  10. Change from baseline in the mean values of self-reported sleep-onset latency (sSOL) recorded in the sleep diary

    Change from baseline in the mean values of self-reported sleep-onset latency (sSOL) measured by sleep diary.

    Time frame: Baseline up to 28 days.

  11. Change from baseline in the mean values of self-reported total sleep time (sTST) recorded in the sleep diary

    Change from baseline in mean self-reported total sleep time measured by sleep diary.

    Time frame: Baseline up to 28 days.

  12. Incidence and severity of adverse events (AE)

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Baseline up to 28 days.

  13. Incidence and severity of serious adverse events (SAE)

    An SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: Baseline up to 28 days.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2024; primary completion for Jan 2025, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2024
First posted
Feb 28, 2024
StartEst.
May 2024
Primary completionEst.
Jan 2025
CompletionEst.
Jan 2025
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06279286
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
May 2024 (estimated)
Primary completion
Jan 2025 (estimated)
Completion
Jan 2025 (estimated)
Last update
Apr 23, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10506

Start the discussion